Drupal-HighWire17<style face="normal" font="default" size="100%">PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 &lt;50%: a multiomics analysis</style>